OncoCyte Corporation (OCX) and Kodiak Sciences Inc. (NASDAQ:KOD) Contrasting side by side

OncoCyte Corporation (NYSEAMERICAN:OCX) and Kodiak Sciences Inc. (NASDAQ:KOD) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OncoCyte Corporation N/A 0.00 15.21M -0.44 0.00
Kodiak Sciences Inc. N/A 0.00 38.35M -1.07 0.00

Table 1 demonstrates OncoCyte Corporation and Kodiak Sciences Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents OncoCyte Corporation (NYSEAMERICAN:OCX) and Kodiak Sciences Inc. (NASDAQ:KOD)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
OncoCyte Corporation 0.00% -219% -119.6%
Kodiak Sciences Inc. 0.00% 0% 0%

Liquidity

OncoCyte Corporation’s Current Ratio is 2.6 while its Quick Ratio is 2.6. On the competitive side is, Kodiak Sciences Inc. which has a 2.3 Current Ratio and a 2.3 Quick Ratio. OncoCyte Corporation is better positioned to pay off short and long-term obligations compared to Kodiak Sciences Inc.

Institutional & Insider Ownership

OncoCyte Corporation and Kodiak Sciences Inc. has shares owned by institutional investors as follows: 21.6% and 13.6%. 1.3% are OncoCyte Corporation’s share owned by insiders. Competitively, insiders own roughly 11.6% of Kodiak Sciences Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OncoCyte Corporation -8.82% -22.5% -32.61% -45.61% -69.9% -66.67%
Kodiak Sciences Inc. -8.65% -4.2% 0% 0% 0% -16.83%

For the past year OncoCyte Corporation was more bearish than Kodiak Sciences Inc.

OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.